businesspress24.com - Medigene Receives EUR 5 Million Milestone Payment from Astellas
 

Medigene Receives EUR 5 Million Milestone Payment from Astellas

ID: 1110982

(Thomson Reuters ONE) -
MediGene AG /
Medigene Receives EUR 5 Million Milestone Payment from Astellas
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, May 7, 2012. MediGene AG (Frankfurt, Prime Standard, MDG)
received a EUR 5 million milestone payment from Astellas Pharma Europe Ltd. This
is the final payment for the transfer of rights for the cancer drug, Eligard(®),
from Medigene to Astellas.

Medigene has now received all milestone payments, totaling EUR 25 million that
were related to the transfer of the Eligard(®) rights. Medigene will continue to
receive 2% royalties on net sales of Eligard(®) achieved by Astellas. With the
transfer of Eligard(®) rights to Astellas, Medigene's obligations and risks
associated with future drug supply, cost of sales, and royalty payments due to
primary licensor Tolmar have ceased.

According to IFRS, Medigene will record this milestone payment as revenue from
discontinued operations.


This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of MediGene AG. Eligard(®) is a registered
trademark of Tolmar Therapeutics Inc. These trademarks may be owned or licensed
in select locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune




diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology.


Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor(at)medigene.com


To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.




press release as pdf:
http://hugin.info/132073/R/1609026/510814.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MediGene AG via Thomson Reuters ONE
[HUG#1609026]



Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  EVRY reports NOK 151 million in EBITA in the first quarter of 2012
Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly
Bereitgestellt von Benutzer: hugin
Datum: 07.05.2012 - 01:31 Uhr
Sprache: Deutsch
News-ID 1110982
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

Martinsried / München


Phone:

Kategorie:

Business News


Anmerkungen:


Diese Pressemitteilung wurde bisher 90 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Medigene Receives EUR 5 Million Milestone Payment from Astellas
"
steht unter der journalistisch-redaktionellen Verantwortung von

MediGene AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von MediGene AG



 

Who is online

All members: 10 589
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 143


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.